Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Difluprednate for inflammation following ocular surgery
NCT00430092Phase 3Completed
- Sponsor
- Sirion Therapeutics, Inc.
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of difluprednate in ocular inflammation (3 arms), sponsored by Sirion Therapeutics, Inc. Primary endpoint: Anterior Chamber Cell Grade of '0' at Day 8. Status: completed.
02
Drugs
difluprednate
03
Conditions
ocular inflammation
Beyond the preview
Go deeper on NCT00430092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00430092.